Literature DB >> 15718048

Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease.

Anna Brück1, Sargo Aalto, Elina Nurmi, Jörgen Bergman, Juha O Rinne.   

Abstract

Patients with Parkinson's disease (PD) have already at the early stages of the disease impaired performance especially in tests measuring frontal lobe functions such as attention. The pathophysiological basis of these deficits is unclear. In the present study, 21 non-demented, non-medicated patients at the early stage of PD and 24 healthy controls underwent a positron emission tomography (PET) scan with 6-[18F]fluoro-L-dopa (Fdopa) as the tracer. In addition, the PD patients performed a neuropsychological test battery, including a test measuring sustained attention (VIG) and a test requiring suppressed attention (Stroop). Both voxel-based Statistical Parametric Mapping (SPM) and automated region of interest (ROI) analysis were employed. Compared to controls, the PD patients had decreased Fdopa uptake in the striatum and a large cortical area of increased Fdopa uptake. The reaction time in the VIG test correlated positively with the Fdopa uptake of the dorsolateral prefrontal cortex and the performance in the Stroop test correlated negatively with the Fdopa uptake in an area including the medial frontal cortex and the anterior cingulate. The results show that cortical Fdopa uptake is increased in early non-medicated PD and suggest that the changes in frontal Fdopa uptake are related to cognitive impairments found in early PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15718048     DOI: 10.1016/j.neurobiolaging.2004.07.014

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  40 in total

1.  An update on brain imaging in parkinsonian dementia.

Authors:  Myria Petrou; Vikas Kotagal; Nicolaas I Bohnen
Journal:  Imaging Med       Date:  2012-04

Review 2.  Neuroimaging and cognition in Parkinson's disease dementia.

Authors:  Lisa C Silbert; Jeffrey Kaye
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

3.  Metabolic brain networks associated with cognitive function in Parkinson's disease.

Authors:  Chaorui Huang; Paul Mattis; Chengke Tang; Kenneth Perrine; Maren Carbon; David Eidelberg
Journal:  Neuroimage       Date:  2006-11-17       Impact factor: 6.556

4.  Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data.

Authors:  Sargo Aalto; Noora M Scheinin; Nina M Kemppainen; Kjell Någren; Marita Kailajärvi; Mika Leinonen; Mika Scheinin; Juha O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-04       Impact factor: 9.236

5.  Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease.

Authors:  Agnese Picco; Silvia Morbelli; Arnoldo Piccardo; Dario Arnaldi; Nicola Girtler; Andrea Brugnolo; Irene Bossert; Lucio Marinelli; Antonio Castaldi; Fabrizio De Carli; Claudio Campus; Giovanni Abbruzzese; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-28       Impact factor: 9.236

Review 6.  Fibrofog and fibromyalgia: a narrative review and implications for clinical practice.

Authors:  Howard M Kravitz; Robert S Katz
Journal:  Rheumatol Int       Date:  2015-01-13       Impact factor: 2.631

7.  Correlations of striatal dopamine synthesis with default network deactivations during working memory in younger adults.

Authors:  Meredith N Braskie; Susan M Landau; Claire E Wilcox; Stephanie D Taylor; James P O'Neil; Suzanne L Baker; Cindee M Madison; William J Jagust
Journal:  Hum Brain Mapp       Date:  2010-06-24       Impact factor: 5.038

8.  A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.

Authors:  Clarence T Li; Matthew Palotti; James E Holden; Jen Oh; Ozioma Okonkwo; Bradley T Christian; Barbara B Bendlin; Laura Buyan-Dent; Sandra J Harding; Charles K Stone; Onofre T DeJesus; Robert J Nickles; Catherine L Gallagher
Journal:  Synapse       Date:  2014-04-22       Impact factor: 2.562

9.  Remedial effects of motivational incentive on declining cognitive control in healthy aging and Parkinson's disease.

Authors:  Helga A Harsay; Jessika I V Buitenweg; Jasper G Wijnen; Maria J S Guerreiro; K Richard Ridderinkhof
Journal:  Front Aging Neurosci       Date:  2010-10-15       Impact factor: 5.750

10.  Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Argelia Esperanza Rojas-Mayorquin; Claudia P Figueiredo; Filipe C Matheus; Laure Ginestet; Caroline Chevarin; Elaine Del Bel; Raymond Mongeau; Michel Hamon; Laurence Lanfumey; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2009-07-21       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.